Clinical Trial

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Study acronym: FIL_MOZART
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-07-01; most recent amendment 2026-01-26.
Status change: Not Yet Recruiting → Recruiting 2025-08-05
Trial Details
NCT Number NCT06492837
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions Follicular Lymphoma
Enrollment 56 participants
Start Date 2024-10-23
Primary Completion 2028-09-15 (estimated)
Study Completion 2033-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-28